Stepwise increase of fidaxomicin in an engineered heterologous host Streptomyces albus through multi-level metabolic engineering

The anti-Clostridium difficile infection (CDI) drug fidaxomicin is a natural polyketide metabolite mainly produced by Micromonosporaceae, such as Actinoplanes deccanensis, Dactylosporangium aurantiacum, and Micromonospora echinospora. In the present study, we employed a stepwise strategy by combinin...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Huang Xie, Yi-Ting Su, Qing-Ting Bu, Yue-Ping Li, Qing-Wei Zhao, Yi-Ling Du, Yong-Quan Li
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	KeAi Communications Co., Ltd. 2024-12-01
Edice:	Synthetic and Systems Biotechnology
Témata:	Fidaxomicin Heterologous expression Streptomyces albus Genome-reduced chassis Metabolic engineering
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2405805X24000930
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!